Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03877926 · ClinicalTrials.gov registry record · Phase 3

VELOCITY: An Anthrax Vaccine Clinical Study

A Phase 3 study of Anthrax, sponsored by Emergent BioSolutions.

Completed
Registry status
Phase 3
Development phase
3,862
Enrollment target
20
Study locations

NCT03877926 is a Phase 3 study of Anthrax that has completed, run by Emergent BioSolutions. The registered enrollment target is 3,862 participants, above the 135-participant average among 6 other Anthrax trials with a reported enrollment target (2761% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03877926, a Phase 3 study of Anthrax, has completed, sponsored by Emergent BioSolutions.

COMPLETED
Registry status
Phase 3
Development phase
3,862 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to that induced by the currently licensed vaccine, BioThrax®, (Anthrax Vaccine Adsorbed; AVA) for post-exposure of anthrax disease.

Conditions Studied

Anthrax

Interventions

  • BIOLOGICAL AV7909
  • BIOLOGICAL BioThrax

Study Locations (20)

Kansas

  • Heartland Research Associates, LLC - Augusta
  • Hutchinson Clinic - Hutchinson
  • Johnson County Clin-Trials, LLC - Lenexa
  • Heartland Research Associates, LLC - Wichita

Alabama

  • Achieve Clinical Research, LLC - Birmingham
  • Optimal Research, LLC - Huntsville
  • Coastal Clinical Research, an AMR company - Mobile

Florida

  • Research Centers of America - Hollywood
  • Optimal Research, LLC - Melbourne
  • New Horizon Research Center, Inc - Miami

Arizona

  • Central Phoenix Medical Clinic, LLC - Phoenix
  • Clinical Research Consortium, an AMR company - Tempe

California

  • California Research Foundation - San Diego
  • Optimal Research, LLC - San Diego

Illinois

  • Christie Clinic, LLC - Champaign
  • Optimal Research, LLC - Peoria

Georgia

  • Meridian Clinical Research, LLC - Savannah

Idaho

  • Advanced Clinical Research - Boise

Trial Details

FieldValue
Enrollment Target 3,862 participants
Start Date 2019-03-11
Est. Completion 2020-08-06
Phase Phase 3

Sponsor

Emergent BioSolutions

34 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03877926

The ClinicalTrials.gov registry entry for NCT03877926 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,862 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 135-participant average among 6 other Anthrax trials with a reported enrollment target (2761% higher). The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anthrax appearing as the primary indexed condition, and to 2 interventions - of which AV7909 is the first listed.

NCT03877926 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Kansas, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT03877926 about?

NCT03877926 is a clinical study titled "VELOCITY: An Anthrax Vaccine Clinical Study". This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to that induced by the currently licensed vaccine, BioThrax®, (Anthrax Vac...

What is the current status of trial NCT03877926?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,862 participants. The study started on 2019-03-11. Estimated completion is 2020-08-06.

What conditions does trial NCT03877926 study?

This clinical trial studies the following conditions: Anthrax.

What interventions are being tested in trial NCT03877926?

The interventions under investigation include: AV7909 (BIOLOGICAL), BioThrax (BIOLOGICAL).

Who is sponsoring clinical trial NCT03877926?

This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03877926 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anthrax

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anthrax

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.